Claus Garbe

82.8k total citations · 13 hit papers
750 papers, 34.4k citations indexed

About

Claus Garbe is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Claus Garbe has authored 750 papers receiving a total of 34.4k indexed citations (citations by other indexed papers that have themselves been cited), including 535 papers in Oncology, 329 papers in Molecular Biology and 154 papers in Immunology. Recurrent topics in Claus Garbe's work include Cutaneous Melanoma Detection and Management (380 papers), Melanoma and MAPK Pathways (227 papers) and Immunotherapy and Immune Responses (135 papers). Claus Garbe is often cited by papers focused on Cutaneous Melanoma Detection and Management (380 papers), Melanoma and MAPK Pathways (227 papers) and Immunotherapy and Immune Responses (135 papers). Claus Garbe collaborates with scholars based in Germany, United States and France. Claus Garbe's co-authors include Ulrike Leiter, Thomas Eigentler, Axel Hauschild, Birgit Schittek, Friedegund Meier, G. Rassner, Dirk Schadendorf, Jürgen Bauer, Helmut Breuninger and Caroline Robert and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Claus Garbe

733 papers receiving 33.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 1.5k citations Paolo A. Ascierto, Brigitte Dréno et al. profile →
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Keith T. Flaherty, Caroline Robert et al. profile →
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
Dermcidin: a novel human antibiotic peptide secreted by sweat glands

2001 527 citations Birgit Schittek, Birgit Sauer et al. profile →
Epidemiology of Melanoma and Nonmelanoma Skin Cancer—The Role of Sunlight

2009 524 citations Ulrike Leiter, Claus Garbe profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Claus Garbe, Célèste Lebbé et al. profile →
Epidemiology of Skin Cancer

2014 446 citations Ulrike Leiter, Thomas Eigentler et al. PubMed profile →
Melanoma

2015 441 citations Dirk Schadendorf, Claus Garbe et al. profile →
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

2016 405 citations Ulrike Leiter, Ulrike Keim et al. profile →
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

2015 371 citations Célèste Lebbé, Jürgen C. Becker et al. European Journal of Cancer profile →
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

2015 340 citations Claus Garbe, Célèste Lebbé et al. European Journal of Cancer profile →
Epidemiology of Skin Cancer: Update 2019

2020 276 citations Ulrike Leiter, Ulrike Keim et al. profile →

Peers

Countries citing papers authored by Claus Garbe

Since Specialization

Citations

This map shows the geographic impact of Claus Garbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Garbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Garbe more than expected).

Fields of papers citing papers by Claus Garbe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus Garbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Garbe. The network helps show where Claus Garbe may publish in the future.

Co-authorship network of co-authors of Claus Garbe

This figure shows the co-authorship network connecting the top 25 collaborators of Claus Garbe. A scholar is included among the top collaborators of Claus Garbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus Garbe. Claus Garbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cutaneous squamous cell carcinoma 1986–2019 in Germany: Incidence, anatomical site, staging, and histologic subtypes 2025 ·European Journal of Cancer ·(unknown), Thomas Dirschka, (unknown), Claus Garbe, Enno Swart, Lutz Schmitz	0
2	Skin cancer in Europe today and challenges for tomorrow 2024 ·Journal of the European Academy of Dermatology and Venereology ·Liève Brochez, Beate Volkmer, Isabelle Hoorens, Claus Garbe, Martin Röcken, Joachim Schüz, David C. Whiteman, Philippe Autier, Rüdiger Greinert, (unknown)	9
3	1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma 2023 ·Annals of Oncology ·Dirk Schadendorf, Reinhard Dummer, K. T. Flaherty, Caroline Robert, Ana Arance, Jan Willem de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, (unknown), Anna Polli, (unknown), Alessandra di Pietro, Paolo A. Ascierto	3
4	602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma 2023 ·Annals of Oncology ·Andrew Haydon, Dirk Schadendorf, Reinhard Dummer, K. T. Flaherty, Caroline Robert, Ana Arance, Jan Willem de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, (unknown), Anna Polli, (unknown), Alessandra di Pietro, Paolo A. Ascierto	2
5	Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma 2022 ·Cancers ·Stephan Forchhammer, (unknown), Gisela Metzler, Claus Garbe, Thomas Eigentler	11
6	Neoadjuvant and adjuvant end-points in health technology assessment in oncology 2021 ·European Journal of Cancer ·Nadia Harbeck, Andreas Schneeweiß, Peter Thuss‐Patience, Kurt Miller, Claus Garbe, Frank Griesinger, Wilfried Eberhardt, Jens Peter Klußmann, Barbara Wollenberg, Marc‐Oliver Grimm, Thomas Zander, Diana Lüftner	9
7	Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos? 2020 ·Cancers ·(unknown), (unknown), Claus Garbe, Heike Niessner, Tobias Sinnberg	39
8	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover 2020 ·Cancers ·Célèste Lebbé, Caroline Dutriaux, Thierry Lesimple, (unknown), Joseph Kerger, L. Thomas, B. Guillot, Filippo de Braud, Claus Garbe, Jean‐Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, P. Vasey, Robert M. Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, (unknown), Brigitte Dréno	32
9	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry 2020 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Teresa Amaral, Ulrike Keim, Ulrike Leiter, Andrea Forschner, Thomas Eigentler, Claus Garbe	16
10	Pitfalls in the characterization of circulating and tissue-resident human γδ T cells 2020 ·Journal of Leukocyte Biology ·(unknown), Daniela Wesch, Hans‐Heinrich Oberg, Christian Peters, (unknown), Benjamin Weide, Claus Garbe, Graham Pawelec, Susanne Sebens, Christoph Röcken, Hisayoshi Hashimoto, Markus Löffler, (unknown), Shahram Kordasti, Dieter Kabelitz, Karin Schilbach, Kilian Wistuba‐Hamprecht	11
11	Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns 2019 ·Journal of the European Academy of Dermatology and Venereology ·Teresa Amaral, (unknown), Dagmar Presser, (unknown), Claus Garbe, Ulrike Leiter	30
12	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma 2017 ·Clinical Cancer Research ·Heike Niessner, Tobias Sinnberg, Corinna Kosnopfel, Keiran S.M. Smalley, Daniela Beck, Christian Praetorius, (unknown), Stefan Beissert, Dagmar Kulms, Martin Schaller, Claus Garbe, Keith T. Flaherty, Dana Westphal, Ines Wanke, Friedegund Meier	34
13	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab 2016 ·Clinical Cancer Research ·Alexander Martens, Kilian Wistuba‐Hamprecht, Jianda Yuan, Michael A. Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Peter Martus, Brigitte Dréno, Paolo A. Ascierto, Jedd D. Wolchok, Graham Pawelec, Claus Garbe, Benjamin Weide	141
14	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses 2014 ·Cancer Immunology Research ·Benjamin Weide, Thomas Eigentler, Annette Pflugfelder, Henning Zelba, Alexander Martens, Graham Pawelec, Leonardo Giovannoni, Pier Adelchi Ruffini, Giuliano Elia, Dario Neri, Ralf Gutzmer, Jürgen C. Becker, Claus Garbe	77
15	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma 2014 ·Clinical Cancer Research ·Henning Zelba, Benjamin Weide, Alexander Martens, Evelyna Derhovanessian, Jithendra Kini Bailur, Christina Kyzirakos, Annette Pflugfelder, Thomas Eigentler, Anna Maria Di Giacomo, Michele Maio, Erik H.J.G. Aarntzen, I. Jolanda M. de Vries, Antje Sucker, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec	35
16	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells 2013 ·Clinical Cancer Research ·Benjamin Weide, Alexander Martens, Henning Zelba, (unknown), Evelyna Derhovanessian, Anna Maria Di Giacomo, Michele Maio, Antje Sucker, Bastian Schilling, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec	210
17	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma 2011 ·Clinical Cancer Research ·Thomas Eigentler, Benjamin Weide, Filippo de Braud, Gianluca Spitaleri, Antonella Romanini, Annette Pflugfelder, Reinerio González‐Iglesias, Annaelisa Tasciotti, Leonardo Giovannoni, Kathrin Schwager, Valeria Lovato, Manuela Kaspar, Eveline Trachsel, Hans D. Menssen, Dario Neri, Claus Garbe	125
18	Suppression of Casein Kinase 1α in Melanoma Cells Induces a Switch in β-Catenin Signaling to Promote Metastasis 2010 ·Cancer Research ·Tobias Sinnberg, Moritz Menzel, Susanne Kaesler, Tilo Biedermann, Birgit Sauer, Sven Nahnsen, Michael Schwarz, Claus Garbe, Birgit Schittek	60
19	[Epiluminescent microscopy and digital image analysis of pigmented skin changes. Meeting 3 and 4 December 1999 in T"ubingen]. 2000 ·PubMed ·(unknown), G. Rassner, Claus Garbe	1
20	Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry 1998 ·International Journal of Cancer ·(unknown), Birgit Schittek, Helmut Breuninger, Evelyn Maczey, (unknown), Karl Sotlar, Ulf Ellwanger, Marcel H. Thelen, G. Rassner, B. Bültmann, Claus Garbe	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact